Watch for Cabenuva, a New Monthly Injectable for HIV

March 2021

Cabenuva (cabotegravir/rilpivirine) will be the first MONTHLY antiretroviral treatment for adults living with HIV.

It’s given as two IM gluteal injections at the same visit. Each Cabenuva kit has one vial of cabotegravir, an integrase inhibitor...and one vial of rilpivirine, a non-nucleoside reverse transcriptase inhibitor.

Viral load suppression with Cabenuva seems similar to standard 3-med oral DAILY regimens, such as Biktarvy or Triumeq.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

COVID-19 Share Facts About the New Viral Vector COVID-19 Vaccine
Immunizations Reduce Risk of Injury and Manage Pain From IM Vaccinations
Asthma Weigh Pros and Cons of SMART for Moderate to Severe Asthma
Headache Start Treatment ASAP for Cluster Headaches
Opioids Stay Vigilant When Prescribing Fentanyl
IBS Sort Out Meds for Irritable Bowel Syndrome
Prediabetes Focus on Lifestyle Changes to Help Tackle Prediabetes
Overactive Bladder Emphasize Nondrug Measures for Overactive Bladder...Not Meds
HIV & AIDS Watch for Cabenuva, a New Monthly Injectable for HIV
COVID-19 Guide Use of Tocilizumab for COVID-19 Based on New Data
Surgery Focus on Safe Use of Local Anesthetics for Post-Op Pain
Pediatrics Assess Best Options for Neonatal Opioid Withdrawal Protocols

Watch for Cabenuva, a New Monthly Injectable for HIV

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Table of Contents